Late Breaking Abstract Parallel Session 3

Nov 11 2025
Convention Center: Hall A (General Session), Concourse Level
10:30 AM - 12:00 PM
Live Streamed
Captured

World Class Speakers

Elliot B. Tapper, MD, FAASLD
Abstract Presenter

Elliot B. Tapper, MD, FAASLD

University of Michigan Medical Center
Rohit Loomba, MD, MHSc, FAASLD
Abstract Presenter

Rohit Loomba, MD, MHSc, FAASLD

University of California, San Diego
Mazen Noureddin
Abstract Presenter

Mazen Noureddin

Houston Research Institute and Houston Methodist Hospital
Andrew Keaveny, MD, FRCPI, FAASLD
Moderator

Andrew Keaveny, MD, FRCPI, FAASLD

Mayo Clinic Florida
Saul Karpen, MD, PhD, FAASLD
Moderator

Saul Karpen, MD, PhD, FAASLD

VCU Stravitz-Sanyal Institute for Liver Disease and Metabolic Health

Description

Late-Breaking Abstract Parallel sessions feature oral presentations from the authors of cutting-edge, highly-rated abstracts submitted for presentation at The Liver Meeting.

Presentations

10:30 AM - 10:45 AM
Apr 29 2026
Washington, D.C.

Lactulose and Tai-Chi Prevent Falls in Patients with Cirrhosis: The LiveSMART Randomized Controlled Trial

Elliot B. Tapper, MD, FAASLD , Abstract Presenter
11:30 AM - 11:45 AM
Apr 29 2026
Washington, D.C.

Dual GLP-1 and Glucagon Receptor Agonist, Mazdutide, Resolved Steatosis in >60% of Participants with MASLD and Obesity in a Multicenter, Randomized Phase 2 Trial

Rohit Loomba, MD, MHSc, FAASLD , Abstract Presenter
11:45 AM - 12:00 PM
Apr 29 2026
Washington, D.C.

A Phase 2, Multicenter, Randomized, Placebo-Controlled Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis

Mazen Noureddin , Abstract Presenter

Objectives

  • Review findings from recent clinical trials related to treatments for cirrhosis, MASLD, and HCC.